Market Insights report
Therapeutic Cannabis products are gaining mainstream prominence, especially after the outbreak of the COVID-19 pandemic, owing to factors such as growing stress and anxiety levels, and the subsequent need for consumers to receive aid. These products which can be consumed as oils, pills, and edibles, among other forms, are readily available in most nations throughout the world, unlike Recreational Cannabis products, which are heavily regulated and are legally sold in only a handful of countries.
The Therapeutic Cannabis market covers cannabinoid-based therapeutic products with low tetrahydrocannabinol (THC) levels. These products are used for medicinal purposes and are intended to improve the quality of life, e.g., by reducing stress and/or anxiety. Prescribed and non-prescribed products are included in our scope and can be consumed through oils, capsules, topicals, e-liquid, edibles, and flowers.
What's included?
This Report on the Therapeutic Cannabis market provides detailed insights into the Therapeutic Cannabis market from a global perspective. Besides all relevant market figures like worldwide revenues from 2016 to 2028, we have deep-dived into regional and country comparisons with a focus on Europe and the Americas.
The Therapeutic Cannabis market was valued at 11.4 billion USD in 2022 and is expected to grow steadily between 2022 and 2028. Innovation in terms of new product development, emergence of new startups, along with robust M&A activity are driving the market. The largest markets include developed countries including the US, Netherlands, Germany, and Canada.
Overview
Market numbers
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)